Zurück zu Projekte

19080.2 PFLS-LS

Selective small molecule LFA-1 inhibitors to restore self-protective immune privilege in non-infectious posterior uveitis.

Zusammenfassung

Selective small molecule LFA-1 inhibitors to restore self-protective immune privilege in non-infectious posterior uveitis.

Weitere Texte

Abstract

Non-infectious posterior uveitis is a sight-threatening inflammatory eye disease which accounts for 10% of preventable blindness, despite currently available therapies. There is a high need for medications which not only provide sight-saving efficacy yet also lasting protection against disease. The goal of this project is to advance such potential therapy, a newly discovered class of small molecule compounds selectively inhibiting the integrin lymphocyte function-associated antigen-1 (LFA-1), to pre-clinical proof-of concept (PoC) and drug candidate status. The current project is expected to be followed by toxicology studies enabling clinical entry and subsequent clinical exploration of an innovative sight-saving regimen, aiming to restore the eyes natural immune privilege for potential freedom of disease.

Beteiligte

Albrecht-Georg Schmidt

Wirtschaftspartner

albrecht.schmidt@allocyte-pharma.com

AlloCyte Pharmaceuticals AG Albrecht-Georg Schmidt Hochbergerstrasse 60C 4057 Basel BS CH

Daniel Gygax

Kontaktperson

daniel.gygax@fhnw.ch

FHNW Fachhochschule Nordwestschweiz Hochschule für Life Sciences Daniel Gygax Gründenstrasse 40 4132 Muttenz BL CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2016-09-30
Enddatum
2018-10-31
Bewilligte Gesamtkosten
CHF 395320.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%